| | Study | Cases | Age/sex | Site | Initial diagnosis | Immunohistochemical staining | Rebiopsy diagnosis | Treatment | Outcome |
| | Index case | 1 case | 56/M | Right neck mass | Follicular lymphoma | CD20+, CD15+, CD30+, CD79a+, PAX5+, bcl-2, and bcl-6+; Ki-67 80% Negative for CD3, CD5, CD10, ALK-1 protein, EMA, and EBV (EBER by ISH) Cyclin D1 equivocal, CD21+
Large cells binucleated and multinucleated were noted | B cell lymphoma, unclassifiable | ACVBP + radiation | Good response |
| | Iwaki et al. [16] | 1 case | 78/F | Ileocecal tumor | Nodular sclerosis cHL | + for CD30, CD20, CD79a, PAX5, BOB.1, and OCT-2, but negative for CD15 Increased level of soluble IL-2 receptor | BCLu-DLBCL/CHL | ABVD | Partial response |
| | Wang et al. [17] | 1 case | 67/F | Left supraclavicular LN, right axillary LN, bilateral inguinal LAD | NA | CD30 and CD15+; CD20−, PAX5, and CD45 were down-regulated; EBV+ | EBV + DLBCL and EBV + CHL | NA | NA |
| | Eberle et al. [9] | 1 case | 55/M | Neck LN | NA | CD20+, CD30+, CD15,
CD79a+, BOB.1+, Oct-2+, p63−, cyclin E−, and HLA-DR4 | GZL | NA | NA |
| | Eberle et al. [9] | 1 case | 67/F | Neck mass | NA | CD20+, CD30+, CD15−,
CD79a+, BOB.1+, Oct-2+, p63+, cyclin E+, and HLA-DR4 | GZL | NA | NA |
| | Eberle et al. [9] | 1 case | 58/F | Inguinal LN | NA | CD20+, CD30−,
CD15, CD79a+, BOB.1+, Oct-2+, p63−, cyclin E−, and HLA-DR4 | GZL | NA | NA |
| | Eberle et al. [9] | 1 case | 26/M | Neck mass | NA | CD20+, CD30+, CD15+, CD79a+, BOB.1+, Oct-2+, p63−, cyclin E+, and HLA-DR3 | GZL | NA | NA |
| | Eberle et al. [9] | 1 case | 91/F | Axillary LN | NA | CD20−, CD30+, CD15+, CD79a+ BOB.1+, Oct-2+, p63+, cyclin E+, and HLA-DR4 | GZL | NA | NA |
| | Eberle et al. [9] | 1 case | 24/F | Cervical LN | NA | CD20+, CD30+, CD15+, CD79a+, BOB.1+, Oct-2+, p63−, cyclin E+, and HLA-DR4 | GZL | NA | NA |
| | Eberle et al. [9] | 1 case | 48/F | Axillary LN | NA | CD20+, CD30+, CD15+, CD79a+, BOB.1+, Oct-2+, p63+, cyclin E+, and HLA-DR1 | GZL | NA | NA |
| | Eberle et al. [9] | 1 case | 85/M | Axillary mass | NA | CD20+, CD30+, CD15− CD79a+, BOB.1+, OCT2+, p63−, cyclin E+, and HLA-DR4 | GZL | NA | NA |
| | Eberle et al. [9] | 1 case | 25/F | Neck LN | NA | CD20− CD30+, CD15+, CD79a−, BOB.1−, Oct-2−, p63−, cyclin E−, and HLA-DR3 | GZL | NA | NA |
| | Quintanilla-Martinez et al. [12] | 1 case (under subheading: “Classical Hodgkin’s lymphoma with immunophenotypic deviations”) | 38 yo | Axillary LN | NA | CD20+, PAX5−, OCT-2−, and CD79a− | CHL morphology but strong CD20 expression in the RS cells | NA | NA |
| | Gualco et al. [14] | 10 cases | 37 y median age | 8 mediastinal, 2 extramediastinal | NA | CD30+ (100%), CD20+ (100%), CD45+ (95%), CD15+ (40%), BOB1+ (40%), OCT2 (50%+, 30%), PAX5+ (90%), bcl-6 (40%), P63 (50%+), and CD79a (70%+) | B cell lymphoma, unclassifiable | combination chemotherapy for non-Hodgkin’s lymphomas | Good response |
| | García et al. [5] | 9 cases | Young males | 3 extramediastinal, 6 mediastinal | NA | CD30+, CD15+ (6/9)
CD45RB+, CD20+, CD79a+, OCT2+, and EBV (2/9) | Shared features of DLBCL and classical HL | NA | NA |
| | Nadeem et al. [10] | 49 cases; 11% extramediastinal | 33.5 Y median age; M > F | 11% extramediastinal, 89% mediastinal | NA | CD20+ (90%), CD30+ (95%), 63% CD15+, and EBV+ (9/22 patients) | GZL | Initial cHL regimens (BEACOPP, ABVD) or DLBCL regimens (CHOP, EPOCH, with or without rituximab) | 7 pts received ABVD, 57% NR and 43% PR; no CRs
7 pts received CHOP; 5 had clinical outcome data available; 80% CR (received consolidation radiation therapy) and 20% PR
7 pts received autologous SCT and 2 of them had relapse in 6 months |
| | Zarate-Osorno et al. [18] | 9 cases: 7 follicular, 1 DLBCL, and 1 large cell immunoblastic | 54-year median age | 7 (primarily nodal)
Name of node not specified in the article | NHL | RS and Hodgkin’s cells were LeuM1 or BerH2+ and LCA− in 8/9 biopsies | HD | 4 chemotherapies
3 chemotherapies + radiation | NA |
|
|
